T. Rowe Price Investment Management, Inc. Agios Pharmaceuticals, Inc. Transaction History

T. Rowe Price Investment Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$21.32 - $34.81 $27,929 - $45,601	-1,310 Reduced 0.14%	928,596 $27.2 Million
Q4 2023 Feb 14, 2024	SELL	$19.97 - $24.53 $2,895 - $3,556	-145 Reduced 0.02%	929,906 $20.7 Million
Q2 2023 Aug 14, 2023	SELL	$21.38 - $29.19 $795,336 - $1.09 Million	-37,200 Reduced 3.85%	930,051 $26.3 Million
Q1 2023 May 15, 2023	SELL	$21.74 - $30.93 $257,879 - $366,891	-11,862 Reduced 1.21%	967,251 $22.2 Million
Q4 2022 Feb 14, 2023	SELL	$24.81 - $31.52 $256,684 - $326,105	-10,346 Reduced 1.05%	979,113 $27.5 Million
Q3 2022 Nov 14, 2022	BUY	$19.51 - $34.14 $19.3 Million - $33.8 Million	989,459 New	989,459 $28 Million

244

59.9M

270K

332K

Ticker AGIO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,818,000
Market Cap $1.94B
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.